Statement

Tariff for supply of Power from Central Generating Stations

Sl.No.	Source	Tariff (P/Unit)
I.	*National Thermal Power Corporation*	
1.	Singrauli STPS	36·27
2.	Korba STPS	37·64
3.	Ramagundam STPS	46·16
4.	Farakka STPS	60·77
5.	Badarpur TPS	71·97
II.	*National Hydro-electric Power Corpn.*	
1.	Baira Siul H.E. Project	36·41
2.	Loktak H.E. Project	53·10
III.	*Nuclear Power Board*	
1.	TAPS	36·99
2.	RAPS	38·09
3.	MAPS	43·29
IV.	*Neyveli Lignite Corporation Ltd.*	
	Neyveli Thermal Power Station-I	45.75

Clearance of Bodhghat Hydel Power project

990. SHRI SURESH PACHOURI: Will the Minister of ENERGY be pleased to state:

(a) whether it is a fact that the Bodhghat Hydel Power Project is still pending clearance with the Centre;

(b) since when the said project is pending for clearance of the Central Government;

(c) by when the clearance to the said proposal is likely to be accorded;

(d) what was the original estimated cost of the project; and

(e) what will be its revised cost after it is cleared by the Central Government?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRIMATI SUSHILA ROHATGI) (a) to (e) The Bodhghat Hydroelectric Power Project (500 MW) was sanctioned by the Planning Commission in Feb., 1979 after techno-economic and environmental clearance at a cost of Rs. 209.3 crores. The proposal regarding transfer of forest land under the Forest (Conservation) Act, 1980, was however submitted by the State Government in Feb., 1983. The clearance under Forest (Conservation) Act, 1980 is yet to be given by the Ministry of Environment, Forest and Wild-life.

Absence of experts for monitoring drugs

991. SHRI GHAN SHYAM SINGH: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the post of Development Commissioner (Drugs) Adviser (Drugs) and Deputy Director (Cost) are lying vacant;

(b) Whether it is also a fact that neither proper monitoring nor proper examination of proposals are being done in the absence of these experts;

(c) Whether it is also a fact that most of the decisions are being taken on arbitrary basis and without any justification;

(d) Whether details of any such instances have come to the notice of his Ministry; and

(e) if so, what steps have been taken to rectify them?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) Action to fill up the posts is taken as and when necessary.

(b) to (d) No., Sir.

(e) Does not arise.

Identification of drugs for delicensing

992. SHRI GHAN SHYAM SINGH: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry identified drugs for delicensing without any criteria;

(b) whether it is a fact that his Ministry had announced criteria for this in December, 1986;

(c) if so, what are those criteria;

(d) whether it is a fact that most of the drugs do not meet those criteria

(e) if so, why a revised list has not been announced despite the fact that six months have passed;

(f) by when the same will be announced;

(g) the names of delicensed drugs for which production has been started alongwith the stage of manufacture;

(h) what was the investment made on each project and what was the production of each drug since the month of production upto the 30th June, 1987; and

(i) what are the names of the companies already producing those drugs alongwith the stage of production?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) No, Sir.

(b) and (c) Yes, Sir. Keeping in view the need to stimulate industrial growth and simplify the industrial licensing policy and procedure, the Scheme of Delicensing was announced on 16-3-85. This scheme was extended to non-MRTP, non-FERA companies for 94 bulk drugs. As per the measures announced in December, 1986 the scheme would be progressively extended subject to the following criteria:—

(1) bulk drugs whose imports are allowed on OGL.

(2) bulk drugs whose production is limited to three producers or less in the organised sector;

(3) bulk drugs whose formulations are of essential and mass consumption nature;

(4) formulations and drug intermediates related to bulk drugs which are delicensed;

The scheme of delicensing would be available for non-MRTP and non-FERA companies only, excepting for new drugs based on clinical trials conducted by MRTP|FERA companies and would not include bulk drugs reserved for public and small scale sector.

(d) All the delicensed bulk drugs meet the criteria.

(e) and (f) Additions|Alterations to the list will be made as and when necessary.

(g) and (h) To the extent details are available, the names of companies who have commenced production of delicensed bulk drugs together with details of investment are given in the enclosed Statement (*See* below)

(i) Details asked for are quite voluminous. Time and labour involved in collection and compilation of information is not commensurate with the results likely to be achieved.